DaVita Inc. (DVA)

NYSE: DVA · Real-Time Price · USD
149.76
+0.93 (0.62%)
Mar 19, 2026, 4:00 PM EDT - Market closed
Market Cap10.04B -11.4%
Revenue (ttm)13.64B +6.5%
Net Income746.80M -20.2%
EPS9.84 -8.3%
Shares Out 66.80M
PE Ratio15.65
Forward PE10.57
Dividendn/a
Ex-Dividend Daten/a
Volume591,723
Open149.79
Previous Close148.83
Day's Range148.83 - 152.18
52-Week Range101.00 - 159.42
Beta0.93
AnalystsHold
Price Target156.75 (+4.32%)
Earnings DateFeb 2, 2026

About DVA

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In... [Read more]

Sector Healthcare
IPO Date Oct 31, 1995
Employees 78,000
Stock Exchange NYSE
Ticker Symbol DVA
Full Company Profile

Financial Performance

In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for DVA stock is "Hold." The 12-month stock price target is $156.75, which is an increase of 4.32% from the latest price.

Price Target
$156.75
(4.32% upside)
Analyst Consensus: Hold
Stock Forecasts

News

DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy an...

1 day ago - PRNewsWire

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global dev...

2 days ago - GlobeNewsWire

DaVita Inc. (DVA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

DaVita Inc. (DVA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

17 days ago - Seeking Alpha

DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference

DENVER, Feb. 24, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will par...

23 days ago - PRNewsWire

20 stocks of companies that delivered a double dose of growth this earnings season

Companies in the S&P 500 achieving double-digit sales growth while improving profit margins include Palantir, Micron, Boeing and Alphabet.

5 weeks ago - Market Watch

DaVita Stock Rallies On Profit Beat, Confident 2026 View

DaVita Inc. (NYSE: DVA) stock surged on Tuesday after the company reported upbeat fourth-quarter earnings and fiscal 2026 guidance.

6 weeks ago - Benzinga

TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings

The AI trade is helping Teradyne (TER), with Diane King Hall pointing to the company's latest earnings as a signal of forward strength. Outside of tech, she notes DaVita's (DVA) earnings beat and guid...

Other symbols: PEPTER
6 weeks ago - Schwab Network

DaVita: Some Success Is Possible, But Volatility Is Still Heavy

DaVita (DVA) delivered a strong earnings beat, driving a 13.5%+ share price surge and reinforcing my positive outlook. DVA's strategy leverages home dialysis, integrated kidney care, and international...

6 weeks ago - Seeking Alpha

DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript

DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript

6 weeks ago - Seeking Alpha

DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump

DaVita projected annual profit above estimates on Monday after reporting better-than-expected fourth-quarter results on steady demand for its kidney dialysis services, sending its shares up 13% in aft...

6 weeks ago - Reuters

DaVita Inc. 4th Quarter 2025 Results

DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 20...

6 weeks ago - PRNewsWire

DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m...

2 months ago - PRNewsWire

DaVita Names New Leaders to Accelerate Care Transformation

Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach DENVER , Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider of kidne...

3 months ago - PRNewsWire

DaVita: More Volatile But Better Upside Than Fresenius

DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare rei...

3 months ago - Seeking Alpha

DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

DaVita Inc. ( DVA) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 11:20 AM EST Company Participants Joel Ackerman - CFO & Treasurer Conference Call Participants Justin Lake - Wolfe...

4 months ago - Seeking Alpha

DaVita Inc. to Participate in Fireside Chat with Wolfe Research

DENVER , Nov. 14, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Con...

4 months ago - PRNewsWire

DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025

Six  new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON , Nov. 4, 2025 /PRNewsw...

4 months ago - PRNewsWire

DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript

DaVita Inc. ( DVA) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Nic Eliason - Group Vice President of Investor Relations Javier Rodriguez - CEO & Executive Director Joel Ac...

5 months ago - Seeking Alpha

DaVita misses quarterly profit estimates on rising costs, lower volumes

DaVita missed Wall Street estimates for third-quarter profit on Wednesday, as the kidney dialysis provider grappled with rising patient care costs and declining treatment volumes.

5 months ago - Reuters

DaVita Inc. 3rd Quarter 2025 Results

DENVER , Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our e...

5 months ago - PRNewsWire

DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives

New U.S. data will offer first-of-its-kind evidence in patients with kidney failure  DENVER , Oct. 20, 2025 /PRNewswire/ -- DaVita today announced the launch of two groundbreaking initiatives aimed to...

5 months ago - PRNewsWire

DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call

DENVER , Oct. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Wednesday, October 29, 2025, at 5:00...

5 months ago - PRNewsWire

DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care

Largest kidney care research arm advances science to inform care delivery DENVER , Aug. 27, 2025 /PRNewswire/ -- As part of its 25th-anniversary celebration, DaVita, a leading provider of comprehensiv...

7 months ago - PRNewsWire

Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows

A ransomware attack that encrypted certain elements of dialysis firm DaVita's network affected 2.7 million people, the U.S. health department's website showed on Thursday.

7 months ago - Reuters

DaVita: Aggressive Buybacks Despite Rising Cost Of Debt

DaVita has reduced the share count by over 10% in the last six months, but interest expenses increased by 50% Y/Y. International revenues grew by 36% Y/Y, and DaVita is pending regulatory approval to ...

7 months ago - Seeking Alpha